DRUG
Cetrorelix Acetate
GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.
Testosterone and Neurovascular Control in Humans
Status
Unknown
Phase
Not applicable
Enrollment
20
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of these studies are to evaluate the role of testosterone on autonomic and vascular function in men.
Full detailed description
Sex hormones play a pivotal role in neurovascular function in humans. In recent years, great strides have been made in elucidating the roles of estrogen and progesterone on autonomic and vascular control in women; however, very little is known about the impact of testosterone in men. Given that low testosterone levels are associated with an increased risk of cardiovascular disease, reduced exercise capacity and vascular dysfunction, it is evident that testosterone plays a pivotal role in autonomic and vascular function in men. Our current understanding of testosterone's effects on neurovascular control are confounded by numerous factors that independently alter autonomic and vascular function such as aging and chronic disease (e.g. cardiovascular disease, metabolic disease). The purpose of these studies are to evaluate the role of testosterone on autonomic and vascular function in young men to better isolate the effects of testosterone from the aforementioned confounding factors. The outcomes of these studies will provide novel information regarding the role of male sex hormones in autonomic and vascular control, and further our understanding of the influence of sex hormones on human physiology.
Interventions
Treatment arms and agents.
DRUG
Testosterone gel
Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
Timeline
From registration to results.
First posted
Mar 26, 2021
Study start
Jun 2021
Primary completion
Dec 2023
Study completion
Dec 2023
Results posted
Not reported
Registry updated
Mar 26, 2021
Outcomes
What the study measures.
Primary outcomes
Muscle sympathetic nerve activity
Time frame · After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone
Multi-unit postganglionic muscle sympathetic nerve activity (MSNA) will be measured by inserting a unipolar tungsten microelectrode into the peroneal nerve near the fibular head of the leg. Neural signals will be amplified, filtered (bandwidth, 700-2,000 Hz), rectified, and integrated (time constant, 0.1 s) to obtain mean voltage neurograms. MSNA will be measured during both trials to evaluate the effect of testosterone on sympathetic activity directed toward the musculature.
Endothelial function
Time frame · After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone
Brachial artery flow-mediated dilation (FMD). Brachial artery FMD measures will be performed non-invasively via Doppler ultrasound.
Forearm blood flow
Time frame · After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone
Forearm blood flow will be measured using Doppler ultrasound at baseline and during stress (e.g. exercise)
Secondary outcomes
Skeletal muscle microvascular blood flow
Time frame · After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone
Microvascular blood flow will be measured using Diffuse correlation spectroscopy.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 35 Years
- Sex
- MALE
- Healthy volunteers
- Yes
Inclusion Criteria: * Moderately active * Free of chronic disease Exclusion Criteria: * congenital or acquired hypogonadism * drug/alcohol dependence * hypertension * current smoker * current opioid or cannabis user * diabetes * inability to provide written consent * parkinson's disease * cardiovascular disease * testosterone use within the last year
Study locations
1 registered sites.
Canada. Showing up to 24 locations stored in the fast local snapshot.
the University of Western Ontario
London, Ontario, Canada
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Cetrorelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
NATural Ovarian Stimulation
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.